Bristol-Myers Squibb
BMY
NZ$78.63
Share price
-1.37%
Change (1 day)
-5.26%
Change (1 year)
Categories
Revenue for Bristol-Myers Squibb (BMY)
Revenue in 2025 (TTM): NZ$80.38 Billion
According to Bristol-Myers Squibb's latest financial reports the company's current revenue (TTM 
) is NZ$79.92 Billion. In 2024 the company made a revenue of NZ$85.64 Billion an increase over the revenue in the year 2023 that were of NZ$71.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Bristol-Myers Squibb from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | NZ$80.38 B | -6.14% |
| 2024 | NZ$85.64 B | 20.34% |
| 2023 | NZ$71.16 B | -2.11% |
| 2022 | NZ$72.70 B | 7.06% |
| 2021 | NZ$67.90 B | 15.24% |
| 2020 | NZ$58.92 B | 51.79% |
| 2019 | NZ$38.82 B | 15.42% |
| 2018 | NZ$33.63 B | 14.98% |
| 2017 | NZ$29.25 B | 4.31% |
| 2016 | NZ$28.04 B | 15.91% |
| 2015 | NZ$24.19 B | 19.39% |
| 2014 | NZ$20.26 B | 1.64% |
| 2013 | NZ$19.93 B | -6.91% |
| 2012 | NZ$21.42 B | -21.31% |
| 2011 | NZ$27.21 B | 7.78% |
| 2010 | NZ$25.25 B | 9.86% |
| 2009 | NZ$22.98 B | -35.23% |
| 2008 | NZ$35.49 B | 48.7% |
| 2007 | NZ$23.86 B | -6.13% |
| 2006 | NZ$25.42 B | -9.51% |
| 2005 | NZ$28.10 B | 14.16% |
| 2004 | NZ$24.61 B | -23.88% |
| 2003 | NZ$32.34 B | -6.59% |
| 2002 | NZ$34.62 B | -25.04% |
| 2001 | NZ$46.18 B | 7.32% |
| 2000 | NZ$43.03 B | 16.11% |
| 1999 | NZ$37.06 B | 6.84% |
| 1998 | NZ$34.69 B | 20.55% |
| 1997 | NZ$28.77 B | 34.97% |
| 1996 | NZ$21.32 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$104.80 B | 31.13% | 🇺🇸 USA |
 Merck MRK | NZ$107.25 B | 34.19% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$82.22 B | 2.87% | 🇺🇸 USA |
 Novartis NVS | NZ$89.30 B | 11.73% | 🇨🇭 Switzerland |
 Sanofi SNY | NZ$79.52 B | -0.50% | 🇫🇷 France |
 AstraZeneca AZN | NZ$92.25 B | 15.42% | 🇬🇧 UK |
 Johnson & Johnson JNJ | NZ$149.88 B | 87.53% | 🇺🇸 USA |
 AbbVie ABBV | NZ$96.25 B | 20.43% | 🇺🇸 USA |
 Amgen AMGN | NZ$57.26 B | -28.36% | 🇺🇸 USA |
 Biogen BIIB | NZ$16.47 B | -79.39% | 🇺🇸 USA |